Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelines
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality and morbidity in individuals with type 2 diabetes mellitus (T2DM). Accordingly, several scientific societies have released clinical practice guidelines to assist health professionals in ASCVD risk management in patients...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1227769/full |
| _version_ | 1797672410550370304 |
|---|---|
| author | Pierre Gourdy Pierre Gourdy François Schiele François Schiele Jean-Michel Halimi Jean-Michel Halimi Jean-Michel Halimi Serge Kownator Samy Hadjadj Paul Valensi Paul Valensi |
| author_facet | Pierre Gourdy Pierre Gourdy François Schiele François Schiele Jean-Michel Halimi Jean-Michel Halimi Jean-Michel Halimi Serge Kownator Samy Hadjadj Paul Valensi Paul Valensi |
| author_sort | Pierre Gourdy |
| collection | DOAJ |
| description | Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality and morbidity in individuals with type 2 diabetes mellitus (T2DM). Accordingly, several scientific societies have released clinical practice guidelines to assist health professionals in ASCVD risk management in patients with T2DM. However, some recommendations differ from each other, contributing to uncertainty about the optimal clinical management of patients with T2DM and established ASCVD or at high risk for ASCVD. Thus, the purpose of this paper is to discuss recent evidence-based guidelines on ASCVD risk stratification and prevention in patients with T2DM, in terms of disparities and similarities. To close the gap between different guidelines, a multidisciplinary approach involving general practitioners, endocrinologists, and cardiologists may enhance the coordination of diagnosis, therapy, and long-term follow-up of ASCVD in patients with T2DM. |
| first_indexed | 2024-03-11T21:29:38Z |
| format | Article |
| id | doaj.art-2d0c151d8ed5415491881ccd18d8bc52 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-03-11T21:29:38Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-2d0c151d8ed5415491881ccd18d8bc522023-09-27T09:49:38ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2023-09-011010.3389/fcvm.2023.12277691227769Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelinesPierre Gourdy0Pierre Gourdy1François Schiele2François Schiele3Jean-Michel Halimi4Jean-Michel Halimi5Jean-Michel Halimi6Serge Kownator7Samy Hadjadj8Paul Valensi9Paul Valensi10Diabetology Department, Toulouse University Hospital, Toulouse, FranceInstitute of Metabolic and Cardiovascular Diseases, UMR1297 INSERM/UT3, Toulouse University, Toulouse, FranceDepartment of Cardiology, University Hospital Besancon, Besancon, FranceEA3920, University of Franche-Comté, Besancon, FranceNéphrologie-Immunologie Clinique, Hôpital Bretonneau, CHU Tours, Tours, FranceEA4245, University of Tours, Tours, FranceInvestigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT), Nancy, FranceCardiology and Vascular Center, Thionville, FranceNantes Université, CHU Nantes, CNRS, INSERM, l’Institut du Thorax, Nantes, France0Unit of Endocrinology-Diabetology-Nutrition, AP-HP, Jean Verdier Hospital, Paris 13 University, Sorbonne Paris Cité, CRNH-IdF, CINFO, Bondy, France1Polyclinique D'Aubervilliers, Aubervilliers, FranceAtherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality and morbidity in individuals with type 2 diabetes mellitus (T2DM). Accordingly, several scientific societies have released clinical practice guidelines to assist health professionals in ASCVD risk management in patients with T2DM. However, some recommendations differ from each other, contributing to uncertainty about the optimal clinical management of patients with T2DM and established ASCVD or at high risk for ASCVD. Thus, the purpose of this paper is to discuss recent evidence-based guidelines on ASCVD risk stratification and prevention in patients with T2DM, in terms of disparities and similarities. To close the gap between different guidelines, a multidisciplinary approach involving general practitioners, endocrinologists, and cardiologists may enhance the coordination of diagnosis, therapy, and long-term follow-up of ASCVD in patients with T2DM.https://www.frontiersin.org/articles/10.3389/fcvm.2023.1227769/fullatherosclerotic cardiovascular diseasetype 2 diabetesrisk assessmentrisk stratificationguidelinesprevention |
| spellingShingle | Pierre Gourdy Pierre Gourdy François Schiele François Schiele Jean-Michel Halimi Jean-Michel Halimi Jean-Michel Halimi Serge Kownator Samy Hadjadj Paul Valensi Paul Valensi Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelines Frontiers in Cardiovascular Medicine atherosclerotic cardiovascular disease type 2 diabetes risk assessment risk stratification guidelines prevention |
| title | Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelines |
| title_full | Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelines |
| title_fullStr | Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelines |
| title_full_unstemmed | Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelines |
| title_short | Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelines |
| title_sort | atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes review of recent evidence based guidelines |
| topic | atherosclerotic cardiovascular disease type 2 diabetes risk assessment risk stratification guidelines prevention |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1227769/full |
| work_keys_str_mv | AT pierregourdy atheroscleroticcardiovasculardiseaseriskstratificationandmanagementintype2diabetesreviewofrecentevidencebasedguidelines AT pierregourdy atheroscleroticcardiovasculardiseaseriskstratificationandmanagementintype2diabetesreviewofrecentevidencebasedguidelines AT francoisschiele atheroscleroticcardiovasculardiseaseriskstratificationandmanagementintype2diabetesreviewofrecentevidencebasedguidelines AT francoisschiele atheroscleroticcardiovasculardiseaseriskstratificationandmanagementintype2diabetesreviewofrecentevidencebasedguidelines AT jeanmichelhalimi atheroscleroticcardiovasculardiseaseriskstratificationandmanagementintype2diabetesreviewofrecentevidencebasedguidelines AT jeanmichelhalimi atheroscleroticcardiovasculardiseaseriskstratificationandmanagementintype2diabetesreviewofrecentevidencebasedguidelines AT jeanmichelhalimi atheroscleroticcardiovasculardiseaseriskstratificationandmanagementintype2diabetesreviewofrecentevidencebasedguidelines AT sergekownator atheroscleroticcardiovasculardiseaseriskstratificationandmanagementintype2diabetesreviewofrecentevidencebasedguidelines AT samyhadjadj atheroscleroticcardiovasculardiseaseriskstratificationandmanagementintype2diabetesreviewofrecentevidencebasedguidelines AT paulvalensi atheroscleroticcardiovasculardiseaseriskstratificationandmanagementintype2diabetesreviewofrecentevidencebasedguidelines AT paulvalensi atheroscleroticcardiovasculardiseaseriskstratificationandmanagementintype2diabetesreviewofrecentevidencebasedguidelines |